BRPI0509683A8 - Vírus de estomatite vesicular geneticamente modificado, vetor de vírus da estomatite vesicular geneticamente modificado, composição imunogênica, e, métodos para imunizar um hospedeiro mamífero contra infecção bacteriana e contra infecção viral - Google Patents

Vírus de estomatite vesicular geneticamente modificado, vetor de vírus da estomatite vesicular geneticamente modificado, composição imunogênica, e, métodos para imunizar um hospedeiro mamífero contra infecção bacteriana e contra infecção viral

Info

Publication number
BRPI0509683A8
BRPI0509683A8 BRPI0509683A BRPI0509683A BRPI0509683A8 BR PI0509683 A8 BRPI0509683 A8 BR PI0509683A8 BR PI0509683 A BRPI0509683 A BR PI0509683A BR PI0509683 A BRPI0509683 A BR PI0509683A BR PI0509683 A8 BRPI0509683 A8 BR PI0509683A8
Authority
BR
Brazil
Prior art keywords
vesicular stomatitis
stomatitis virus
genetically modified
modified vesicular
immunizing
Prior art date
Application number
BRPI0509683A
Other languages
English (en)
Inventor
Kirkwood Clarke David
Michael Hendry Roger
A Udem Stephen
Lee Parks Christopher
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0509683A publication Critical patent/BRPI0509683A/pt
Publication of BRPI0509683A8 publication Critical patent/BRPI0509683A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20241—Use of virus, viral particle or viral elements as a vector
    • C12N2760/20243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20261—Methods of inactivation or attenuation
    • C12N2760/20264—Methods of inactivation or attenuation by serial passage
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

VÍRUS DA ESTOMATITE VESICULAR GENETICAMENTE MODIFICADO, VETOR DE VÍRUS DA ESTOMATITE VESICULAR GENETICAMENTE MODIFICADO, COMPOSIÇÃO IMUNOGÊNICA, E, MÉTODOS PARA IMUNIZAR UM HOSPEDEIRO MAMÍFERO CONTRA INFECÇÃO BACTERIANA E CONTRA INFECÇÃO VIRAL. A presente invenção refere-se amplamente à atenuação sinérgica do vírus da estomatite vesicular (VSV). Mais particularmente, a invenção refere-se à identificação de classes de mutação combinadas que atenuam sinergicamente a patogenicidade dos vetores de VSV em mamíferos e às suas composições imunogênicas.
BRPI0509683A 2004-04-09 2005-04-05 Vírus de estomatite vesicular geneticamente modificado, vetor de vírus da estomatite vesicular geneticamente modificado, composição imunogênica, e, métodos para imunizar um hospedeiro mamífero contra infecção bacteriana e contra infecção viral BRPI0509683A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56121404P 2004-04-09 2004-04-09
US64490205P 2005-01-19 2005-01-19
PCT/US2005/011499 WO2005098009A2 (en) 2004-04-09 2005-04-05 Synergistic attenutation of vesicular stomatitis virus, vectors thereof and immunogenic compositions thereof

Publications (2)

Publication Number Publication Date
BRPI0509683A BRPI0509683A (pt) 2007-10-30
BRPI0509683A8 true BRPI0509683A8 (pt) 2015-12-22

Family

ID=35125676

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509683A BRPI0509683A8 (pt) 2004-04-09 2005-04-05 Vírus de estomatite vesicular geneticamente modificado, vetor de vírus da estomatite vesicular geneticamente modificado, composição imunogênica, e, métodos para imunizar um hospedeiro mamífero contra infecção bacteriana e contra infecção viral

Country Status (15)

Country Link
US (2) US8287878B2 (pt)
EP (1) EP1756287B1 (pt)
JP (3) JP2007535918A (pt)
KR (1) KR101255016B1 (pt)
AR (1) AR048596A1 (pt)
AU (1) AU2005230687B8 (pt)
BR (1) BRPI0509683A8 (pt)
CA (1) CA2561245C (pt)
DK (1) DK1756287T3 (pt)
ES (1) ES2535310T3 (pt)
IL (2) IL178395A (pt)
MX (1) MX343109B (pt)
NZ (1) NZ550150A (pt)
TW (1) TW200602495A (pt)
WO (1) WO2005098009A2 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007535918A (ja) * 2004-04-09 2007-12-13 ワイス 水疱性口内炎ウイルスの相乗的弱毒化、そのベクター及びその免疫原性組成物
EP2007883B1 (en) * 2006-04-20 2011-12-28 Wyeth LLC Purification processes for isolating purified vesicular stomatitis virus from cell culture
WO2009025770A2 (en) * 2007-08-17 2009-02-26 Wyeth A heterologous prime-boost immunization regimen
AU2008340319A1 (en) * 2007-12-21 2009-07-02 Wyeth Llc Genetically modified attenuated vesicular stomatitis virus, compositions and methods of use thereof
CN105039266A (zh) * 2008-03-14 2015-11-11 赛诺菲巴斯德生物制剂有限责任公司 复制缺陷型黄病毒疫苗和疫苗载体
US8481297B2 (en) * 2009-01-08 2013-07-09 Yale University Compositions and methods of use of an oncolytic vesicular stomatitis virus
US20110014228A1 (en) * 2009-06-15 2011-01-20 New York University Il23 modified viral vector for recombinant vaccines and tumor treatment
US20120171246A1 (en) 2009-09-10 2012-07-05 Yale University Immunization to reduce neurotoxicity during treatment with cytolytic viruses
WO2011056993A1 (en) 2009-11-04 2011-05-12 Yale University Compositions and methods for treating cancer with attenuated oncolytic viruses
US9402891B2 (en) * 2011-06-08 2016-08-02 Ohio State Innovation Foundation Norovirus immunogens and related materials and methods
US9347065B2 (en) * 2012-03-29 2016-05-24 International Aids Vaccine Initiative Methods to improve vector expression and genetic stability
WO2014093602A1 (en) * 2012-12-14 2014-06-19 Profectus Biosciences, Inc. Compositions and methods for treating and preventing hepatitis c virus infection
WO2015077714A1 (en) 2013-11-22 2015-05-28 Yale University Chimeric vsv virus compositions and methods of use thereof for treatment of cancer
SG11201607287XA (en) * 2014-03-01 2016-09-29 Univ Texas Recombinant isfahan viral vectors
JP7420334B2 (ja) * 2015-06-25 2024-01-23 株式会社カネカ 液体注入方法
US9925258B2 (en) 2015-10-02 2018-03-27 International Aids Vaccine Initiative Replication-competent VSV-HIV Env vaccines
US10279027B2 (en) 2015-10-02 2019-05-07 International Aids Vaccine Initiative Transgenic Vero-CD4/CCR5 cell line
EP3436054B2 (en) 2016-09-13 2022-07-27 Allergan, Inc. Stabilized non-protein clostridial toxin compositions
AU2017327663A1 (en) * 2016-09-14 2019-04-04 Université Catholique de Louvain Modified VSV-G and vaccines thereof
US20200276297A1 (en) * 2017-09-15 2020-09-03 Ohio State Innovation Foundation Vaccines and methods of making and using vaccines for prevention of respiratory syncytial virus (rsv) infections
WO2019191070A1 (en) * 2018-03-26 2019-10-03 University Of Miami Recombinant viral vector and uses thereof
AU2019308266A1 (en) 2018-07-17 2021-03-11 Yale University Methods for treatment of cancer using chikungunya-VSV chimeric virus
WO2021211760A1 (en) * 2020-04-14 2021-10-21 The Regents Of The University Of California Large sequence pan-coronavirus vaccine compositions
MX2022013030A (es) 2020-04-17 2023-03-09 Regeneron Pharma Ensayos de deteccion para anticuerpos neutralizantes de coronavirus.
US20230149536A1 (en) 2020-04-17 2023-05-18 Vyriad, Inc. Compositions for treating and/or preventing coronavirus infections
CN117752779A (zh) * 2020-06-15 2024-03-26 睿丰康生物医药科技(浙江)有限公司 一种冠状病毒刺突蛋白包膜替换型载体疫苗及其构建方法
US20240067934A1 (en) * 2020-12-16 2024-02-29 Humane Genomics Inc. Modular viral genomes and methods of producing the same
WO2022239724A1 (en) * 2021-05-10 2022-11-17 Okinawa Institute Of Science And Technology School Corporation A modified rhabdovirus having a reduced toxicity
WO2022246041A2 (en) * 2021-05-20 2022-11-24 Achelois Biopharma, Inc. Compositions and methods for multivalent surface display on enveloped particles
CN115725657B (zh) * 2022-09-16 2024-06-04 中国科学院广州生物医药与健康研究院 一种节段化的水泡性口炎病毒载体及其制备方法和应用
WO2024159071A1 (en) 2023-01-27 2024-08-02 Regeneron Pharmaceuticals, Inc. Modified rhabdovirus glycoproteins and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5258454A (en) 1988-09-01 1993-11-02 Riso National Laboratory Peptide synthesis method and solid support for use in the method
US5556747A (en) 1990-07-09 1996-09-17 E. R. Squibb & Sons, Inc. Method for site-directed mutagenesis
US5550251A (en) 1991-12-12 1996-08-27 The Trustees Of The University Of Pennsylvania Alicyclic peptidomimetics
DK0702085T4 (da) 1994-07-18 2010-04-06 Conzelmann Karl Klaus Prof Dr Rekombinant infektiøs ikke-segmenteret negativ-strenget RNA-virus
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
US5789166A (en) 1995-12-08 1998-08-04 Stratagene Circular site-directed mutagenesis
WO1998050529A1 (en) * 1997-05-02 1998-11-12 The Uab Research Foundation Attenuation of negative stranded rna viruses by rearrangement of their genes and uses thereof
US6596529B1 (en) * 1997-05-02 2003-07-22 Uab Research Foundation Manipulation of negative stranded RNA viruses by rearrangement of their genes and uses thereof
US6673572B2 (en) 1998-06-03 2004-01-06 Wyeth Holdings Corporation Methods for rescue of RNA viruses
AU2002365029A1 (en) * 2001-07-20 2003-06-10 The University Of Georgia Research Foundation, Inc. Attenuated rabies virus with nucleoprotein mutation at the phosphorylation site for vaccination against rabies
WO2004022716A2 (en) * 2002-09-09 2004-03-18 University Of Tennessee Research Foundation Recombinatant mutants of rhabdovirus and methods of use thereof
KR101020532B1 (ko) * 2003-06-09 2011-03-09 와이어쓰 엘엘씨 ｃＤＮＡ로부터의 비분절 네가티브 쇄 ＲＮＡ 바이러스의 회수를 위한 개선된 방법
GB0322750D0 (en) * 2003-09-30 2003-10-29 Givaudan Sa Organic compounds
JP2007535918A (ja) * 2004-04-09 2007-12-13 ワイス 水疱性口内炎ウイルスの相乗的弱毒化、そのベクター及びその免疫原性組成物
JP5554580B2 (ja) * 2010-01-27 2014-07-23 日本クロージャー株式会社 合成樹脂製スパウト
JP5081329B1 (ja) * 2012-06-06 2012-11-28 有限会社ユニバーサルライフ ガードル

Also Published As

Publication number Publication date
AU2005230687A8 (en) 2011-08-11
ES2535310T3 (es) 2015-05-07
EP1756287B1 (en) 2015-02-25
WO2005098009A2 (en) 2005-10-20
MX343109B (es) 2016-10-25
IL178395A0 (en) 2007-02-11
US20070218078A1 (en) 2007-09-20
JP2011244825A (ja) 2011-12-08
KR20070004822A (ko) 2007-01-09
AU2005230687A1 (en) 2005-10-20
US8647638B2 (en) 2014-02-11
JP2014087352A (ja) 2014-05-15
AU2005230687B2 (en) 2011-07-21
AR048596A1 (es) 2006-05-10
US20130023032A1 (en) 2013-01-24
EP1756287A2 (en) 2007-02-28
JP5779226B2 (ja) 2015-09-16
NZ550150A (en) 2009-05-31
TW200602495A (en) 2006-01-16
IL224774A (en) 2014-07-31
JP2007535918A (ja) 2007-12-13
US8287878B2 (en) 2012-10-16
WO2005098009A3 (en) 2005-12-29
CA2561245C (en) 2013-06-18
BRPI0509683A (pt) 2007-10-30
AU2005230687B8 (en) 2011-08-11
CA2561245A1 (en) 2005-10-20
IL178395A (en) 2013-03-24
KR101255016B1 (ko) 2013-04-17
DK1756287T3 (en) 2015-03-23

Similar Documents

Publication Publication Date Title
BRPI0509683A8 (pt) Vírus de estomatite vesicular geneticamente modificado, vetor de vírus da estomatite vesicular geneticamente modificado, composição imunogênica, e, métodos para imunizar um hospedeiro mamífero contra infecção bacteriana e contra infecção viral
BR112022016054A2 (pt) Composições imunogênicas para coronavírus e usos das mesmas
BR0111732A (pt) Prodrogas de 2-deóxi-beta-l-nucleosìdeos
CR20220675A (es) Análogos de nucleósido de 1´- ciano y usos de los mismos
BRPI0312173B8 (pt) vetor e processo para a preparação de partículas infecciosas de vírus do sarampo
BRPI0407699A (pt) Inibidores de rna-polimerase dependente de rna de vìrus de hepatite c e composições e tratamentos que os utilizam
WO2007124479A3 (en) Avian influenza viruses, vaccines, compositions, formulations, and methods
EA200800932A1 (ru) Модифицированные 4`-нуклеозиды в качестве противовирусных агентов
MA31496B1 (fr) Inhibiteurs macrocycliques innovants de la replication du virus de l'hepatite c
ATE476983T1 (de) Immunostimulierende polynukleotide sequenzen zur verwendung bei der verhinderung und behandlung von viralen erkrankungen der atemwege
BRPI0716518B8 (pt) vacina de ipv e uso da mesma
BR9909197A (pt) Derivados 1,3,5-triazina tri-substituìdos para o tratamento de infecções por hiv
BRPI0514425A (pt) inibidores de rna polimerase dependente de rna do vìrus da hepatite c, e composições e tratamentos usando os mesmos
PH12021550479A1 (en) Dengue vaccine unit dose and administration thereof
BRPI0607374B8 (pt) vacinas de vesículas baseadas em gna1870 para proteção de amplo espectro contra doenças causadas por neisseria meningitidis
CO6220833A2 (es) Inmuno reguladores preparaciones y composiciones que incluyen los inmuno-reguladores pruebas para evaluar la actividad de los inmuno-reguladores y preparaciones y composiciones que incluyen los mismos y metodos
CR20230100A (es) Compuestos fosfolípidos y usos de los mismos
CL2022002412A1 (es) Vacuna
BRPI0516542A (pt) composição de vacina eficaz na prevenção ou melhora de infecção pelo vìrus da influenza aviária; método para prevenir ou melhorar a eclosão de infecção pelo vìrus da influenza aviária
BR112023021654A2 (pt) Vacina contra vírus
MX2007002659A (es) Composicion vacunal contra el virus de la hepatitis c.
BR112022019207A2 (pt) Composições de vacina para coronavírus e métodos de uso das mesmas
BR112021026193A2 (pt) Composições e métodos para tratar ou prevenir infecções oculares com filociclovir
WO2022214678A3 (en) Human metapneumo virus vaccine
WO2022109317A9 (en) Anti-influenza antibodies and combinations thereof

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: C12N 15/86

Ipc: C12N 7/01 (2006.01), C12N 15/86 (2006.01), C12N 15

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]